Illumina (ILMN) Other PTs Raised at Cowen Into Q2 Earnings Season

Cowen analyst Doug Schenkel raised price target on a host of genetic diagnostic tools makers today, including Illumina (NASDAQ: ILMN) - which was raised to $300. The changes come ahead of Q2 earnings season, which the analyst views as "mixed" for the sector. Upside vs. consensus is expected from ILMN, BDX, CPHD and HOLX. FLDM, QGEN, MYGN and GHDX may come up a bit short – but the firm said "it is complicated.".

Top picks in the sector (ILMN, BDX, CPHD), look "well positioned," the analyst said.

Price Target Changes:

• Illumina (NASDAQ: ILMN) (Outperform) to $300 (from $264)
• Fluidigm Corporation (NASDAQ: FLDM) (Outperform) to $32 (from $45).
• Hologic (NASDAQ: HOLX) (Market Perform) to $40 (from $35)
• Luminex Corp. (NASDAQ: LMNX) (Market Perform) to $18 (from $17)
• Qiagen (NASDAQ: QGEN) (Market Perform) to $23 (from $21)

For an analyst ratings summary and ratings history on Illumina click here. For more ratings news on Illumina click here.

Shares of Illumina closed at $218.36 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c